| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5601839 | ALLERGAN | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US5834010 | ALLERGAN | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US7179483 | ALLERGAN | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081251 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081249 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US6743441 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081252 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081250 | ALLERGAN | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
Oxytrol is owned by Allergan.
Oxytrol contains Oxybutynin.
Oxytrol has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Oxytrol are:
- US5601839
- US5834010
- US7179483
- US7081251
- US7081249
- US6743441
- US7081252
- US7081250
Oxytrol was authorised for market use on 26 February, 2003.
Oxytrol is available in film, extended release;transdermal dosage forms.
Oxytrol can be used as treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
The generics of Oxytrol are possible to be released after 26 April, 2020.
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 26 February, 2003
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL family patents
